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Abstract
Two stage instrumental variable methods are commonly used to estimate the causal effects of 
treatments on survival in the presence of measured and unmeasured confounding. Two stage 
residual inclusion (2SRI) has been the method of choice over two stage predictor substitution 
(2SPS) in clinical studies. We directly compare the bias in the causal hazard ratio estimated by 
these two methods. Under a principal stratification framework, we derive a closed form solution 
for asymptotic bias of the causal hazard ratio among compliers for both the 2SPS and 2SRI 
methods when survival time follows the Weibull distribution with random censoring. When there 
is no unmeasured confounding and no always takers, our analytic results show that 2SRI is 
generally asymptotically unbiased but 2SPS is not. However, when there is substantial 
unmeasured confounding, 2SPS performs better than 2SRI with respect to bias under certain 
scenarios. We use extensive simulation studies to confirm the analytic results from our closed-
form solutions. We apply these two methods to prostate cancer treatment data from SEER-
Medicare and compare these 2SRI and 2SPS estimates to results from two published randomized 
trials
Keywords
instrumental variable; two-stage residual inclusion; two-stage predictor substitution; unmeasured 
confounding; survival; bias
1. Introduction
Evaluating the effectiveness of treatment and identifying the causal relationship between 
exposure and disease are critical objectives for clinical and health services researchers. 
Confounding is often a concern when analyzing nonrandomized observational studies and 
even randomized studies with non-compliance [1]. Instrumental variable (IV) methods are 
increasingly being used in clinical comparative effectiveness studies to potentially control 
for both measured and unmeasured confounding. Angrist et al.[2] defined the IV for causal 
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effects of treatment on outcome to be a variable satisfying the following five assumptions: i) 
The potential outcomes on one subject are unrelated with the particular assignment of 
treatment to the other subjects; ii) IV is randomly (or ignorably) assigned; iii) Any effect of 
IV on the outcome must be mediated by treatment received (the exclusion restriction);iv) IV 
has nonzero effect on treatment received; v) There are no defiers. (for details see section 2)
In a recent clinical study, we were interested in comparing the effectiveness of two 
treatments for prostate cancer in elderly men using SEER-Medicare, a large national 
observational database. Specifically, we planned to use IV methods to estimate the effect of 
the addition of external beam radiation therapy (EBRT) to androgen suppression therapy 
(ADT) in improving overall survival in men with locally advanced prostate cancer. We 
considered a commonly used IV in health services research: local area treatment patterns 
defined by the percentage of active treatment in hospital referral regions (HRR). This IV has 
been shown to capture regionally distinct structural variation in care [3]. Such variation is 
not fully explained by patient characteristics. Further, this IV varies across HRRs and is 
strongly associated with treatment assignment. Finally, it is balanced across important 
observed prognostic factors. Although there is an extensive literature on the importance of 
choosing an appropriate instrument, less attention has been paid to using the appropriate 
modeling approach once an IV is selected.
Recently, there has been rapid uptake and widespread use of two IV based analytic 
approaches called two-stage residual inclusion (2SRI) and two-stage predictor substitution 
(2SPS)[4, 5]. These methods have been used to correct for bias due to endogeneity in non-
linear models for both binary and time-to-event outcomes. Among these two IV approaches, 
2SRI was shown to consistently estimate a conditional causal parameter under certain 
assumptions [4] and has been adopted as the method of choice in clinical research studies 
involving survival outcomes[6, 7, 8]. The conditional causal parameter that Terza et al.[4] 
consider is only identified by making homogeneity assumptions that go beyond the five 
assumptions for a valid IV defined in the first paragraph. Angrist et al. [2] showed that under 
these five assumptions for a valid IV, the only treatment effect that is identified is the 
average treatment effect for the compliers, where the the compliers are the subjects who 
would take the treatment if encouraged to do so by the IV but would not take the treatment if 
not encouraged by the IV; this is called the local average treatment effect (LATE). In the 
context of a binary outcome, Cai et al.[5] demonstrated that both the 2SRI and 2SPS 
methods generated biased estimates of LATE among compliers for binary outcome. In this 
paper, we focus on the properties of 2SPS and 2SRI as estimators of the LATE for time-to-
event data.
Despite the fact that there is growing interest in applying two stage IV methods to time-to-
event data, little is known about the potential bias of using such methods to estimate LATE 
among compliers. We derive closed form expressions of the bias and conduct extensive 
simulations to quantify this bias. We then apply both of the two-stage IV methods to our 
prostate cancer treatment data and compare them to the results from two published 
randomized clinical trials [9, 10]
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2. Notation, Assumptions, Compliance Categories, and Model
2.1. Notation
Following the notation of Cai et al.[5] and Nie et al.[11], an N-dimensional vector of binary 
IV is represented by Ṟ. An IV value of 1 represents encouragement to receive the active 
treatment and 0 represents no encouragement to receive the active treatment. In a RCT 
setting, where the IV is the randomized assignment, then an IV value of 1 represents random 
assignment to treatment and 0 represents random assignment to control; in the prostate 
cancer observational study described in the introduction, an IV value of 1 represents a high 
local area rate (above median) of adding EBRT to ADT and 0 represents a low local area 
rate (below the median) of adding EBRT to ADT. The ith element Ri = 1 implies that subject 
i is encouraged to receive the active treatment, whereas Ri = 0 indicates that subject i is not 
encouraged to receive the active treatment. Let ẔṞ be an N-dimensional vector of potential 
treatment received given Ṟ, and ith element  indicates that subject i receives the active 
treatment and  means that subject i receives the control under Ṟ.
Similarly, we define ṮṞ,Ẕ to be an N-dimensional vector of potential survival time under Ṟ 
and Ẕ, and ith element  is the potential survival time for subject i under Ṟ and Ẕ. Let 
ḺṞ, Ẕ to be an N-dimensional vector of potential censoring time under Ṟ and Ẕ, and ith 
element  is the potential censoring time for subject i under Ṟ and Ẕ.
We define Y̱Ṟ, Ẕ=min{ṮṞ,Ẕ, ḺṞ,Ẕ}, the elementwise minimum of potential censoring and 
survival times, to be an N-dimensional vector of potential observed follow up time under Ṟ 
and Ẕ, and ith element  represents the potential follow up time for subject i under Ṟ 
and Ẕ. Let  indicates whether subject i is observed to terminate by 
failure ( ) or by censoring ( ) given Ṟ and Ẕ. The vector Xi̱ represents 
measured confounding variables for subject i.
2.2. Assumptions
The main assumptions we will make for causal modeling are the five assumptions made by 
Angrist et al. [2], and a random censoring assumption for the survival setting.
1. Stable Unit Treatment Value Assumption (SUTVA)[12, 13]
a. if , then 
b.
if  and , then 
The SUTVA assumption says that the potential outcomes for subject i are 
not related with the treatment status of other subjects such that we can write 
, , , ,  as , , , , 
respectively. The SUTVA assumption also implies the assumption of 
consistency, such that the value of the potential outcome given a treatment 
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remains unchanged no matter what the treatment assignment mechanism is 
[12]
2. Independence of the instrument Ṟ [14]:
Conditional on a vector of confounders X̱, the random vector (Y̱Ṟ,Ẕ, ṮṞ,Ẕ,ḺṞ,Ẕ,ẔṞ) 
is independent of Ṟ. In a randomized trial where R is the IV, the independence 
assumption holds without conditioning on X̱.
3. Exclusion Restriction
∀Ẕ,Ṟ, and Ṟ′, we have:
ṮṞ,Ẕ=ṮṞ′,Ẕ,ḺṞ,Ẕ = ḺṞ′,Ẕ, Y̱Ṟ′,Ẕ = Y̱Ṟ′,Ẕ, This assumption implies that any effect of 
IV on potential outcomes must be through its effect on treatment actually received. 
Thus, we can write , ,  as , ,  by combining the exclusion 
restriction and SUTVA assumptions.
4. Non-zero Average Causal Effect of Ṟ on Ẕ
This assumption means the IV is correlated with treatment received.
5. Monotonicity [15]
This assumption rules out the existence of defiers. No subject always does the 
opposite of the treatment assigned.
6. Independent censoring
The distribution of potential survival time ṮṞ,Ẕ is independent of the distribution of 
potential censoring time ḺṞ,Ẕ.
2.3. Compliance Categories
Under the framework of principal stratification and potential outcomes [2, 16], subjects in a 
two-arm randomized trial can be categorized into 4 principal strata: Always takers (AT) are 
subjects who always take the treatment regardless of assignments (Z1 = 1, Z0 = 1); 
Compliers (C) are subjects who comply with their assignments (Z1 = 1, Z0 = 0); Never 
takers (NT) are the subjects who never take the treatment no matter which group they are 
assigned to (Z1 = 0, Z0 = 0); Defiers (D) are the subjects who take the treatment opposite of 
their assignments (Z1 = 0, Z0 = 1).
2.4. Model
We first define the probability of receiving the treatment Pr(R = 1) = r, the probability of 
being a always taker Pr(AT) = ρa, and the probability of being a complier Pr(C) = ρc. We 
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also define the probability of being a defier Pr(D) = ρd, but under the monotonicity 
assumption, there are no defiers so that ρd = 0. Hence, the probability of being a never taker 
Pr(NT) is equal to 1 − ρa − ρc.
We assume both potential censoring time and potential survival time follow the Weibull 
distribution with the same shape parameter α. The potential censoring time for the subjects 
in each principal strata follows Weibull(α, λ), and we define the parameters of the 
probability distribution of potential survival time for each principal strata as follows:
We also examined scenarios in which different shape parameters α’s are assumed for the 
potential censoring time and the potential survival time. These details are given in Appendix 
E. The density of Weibull distribution is f(t) = (α/K)(t/K)K−1exp(−(t/K)α) and the hazard rate 
is h(t) = αK−αtα−1. In the case of Weibull regression with covariates X, K−α can be 
reparameterized as exp(βX). The hazard rate for the compliers if treated is 
. The hazard rate for the compliers if not treated is 
. Hence, the log causal hazard ratio ϕ for the compliers is the 
difference between two log hazard rates:
3. Two Stage Predictor Substitution (2SPS) Method
The 2SPS method is frequently used and simple to implement [4]. In the first stage, the 
treatment received Z is regressed on the IV-treatment assignment R, and let P = E (Z∣R). In 
the second stage, a log linear model including P, defined as:
is fitted to estimate the coefficient ξ. This is 2SPS estimator of the log causal hazard ratio. 
We first derive a closed form expression to the probability limit of the maximal likelihood 
estimator (M.L.E) of ξ, then take the difference between this probability limit and true log 
causal parameter ϕ for the expression of the asymptotic bias of the 2SPS estimator as an 
estimator of the log causal hazard ratio for compliers.
3.1. Probability limit of M.L.E of causal parameter
Let P̂ denote the predicted value from the estimated binary regression model. i.e., P̂ = 
Ê(Z∣R). When P̂ is substituted for P, the second stage Weibull model becomes:
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Let ξ̂* and ξ̂ denote the estimators (M.L.E) of ξ* and ξ respectively. As sample size n → ∞, 
P̂ → P, , and . Therefore, . To derive closed form expression for the 
asymptotic bias, we need to re-express ξ in terms of parameters specified in Section 2 under 
the principal stratification framework.
Only always takers receive the treatment when assigned to control (R = 0). Both always 
takers and compliers take the treatment when assigned to treatment (R = 1). Thus, it can be 
shown that [5]:
Since P = {p0, p1} is an one-to-one transformation of R = {0, 1}, we have the following for 
the second stage Weibull regression:
(1)
and,
(2)
Instead of working with a second stage model involving P, we can work with a model 
involving R instead. Solving (1) and (2), we have:
(3)
The log linear model including R assumes two underlying Weibull distributions of the same 
shape parameter α*, Weibull(α*, K0) and Weibull(α*, K1), for subjects assigned to control 
(R = 0) and treatment (R = 1) respectively. Thus, (3) can be expressed as:
(4)
It is worth noting that both follow up times of subjects assigned to control, denoted as Y∣R = 
0, and follow up times of subjects assigned to treatment, denoted as Y∣R = 1, actually follow 
mixture distributions consisting of three different Weibull distributions. Details are given in 
Appendix A. However, the second stage Weibull model of 2SPS method imposes the two 
Weibull distributions, with the same shape parameter α* but different scale parameters K0, 
K1, upon subjects assigned to treatment (R = 1) or assigned to control (R = 0) respectively. 
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Thus, the M.L.E of α*, K0, K1 are derived by maximizing the likelihood function Ln (α*, 
K0, K1) that consists of products of two Weibull densities: Weibull(α*, K0) and Weibull(α*, 
K1).
Let α̂* denote the M.L.E of α* and We set , the 
expectation of score equation derived from profile likelihood of α*, equal to 0 and let  be 
the solution. Under the assumptions stated in Section 2 and consistency of M.L.E, the 
probability limit of the estimator α̂* is . Details are given in Appendix C. Once the 
parameters of the principal strata are defined,  can be solved numerically using a root-
finding algorithm such as the “bisection” method. Let K̂0, K̂1 be the M.L.Es of the two scale 
parameters K0, K1 respectively. After the value of  is determined, the probability limits of 
the estimators K̂0, K̂1 can be derived as follows:
(5)
and,
(6)
The detailed steps of the derivation of (5) and (6) are given in Appendix C. By substituting 
(5) and (6) into (4), we derive the expression of log causal hazard ratio ξ as the following:
(7)
Thus, (7) is the closed-form expression of the probability limit of the log causal hazard ratio 
estimator ξ̂* from the 2SPS Weibull model.
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3.2. Bias analysis
The asymptotic bias of the causal parameter ξ of the 2SPS Weibull regression model is 
simply the difference between the true log causal hazard ratio ϕ and the derived closed form 
expression of ξ, such that
(8)
We can re-paramterize  in (8) with one additional parameter 
 as the following:
(9)
Δ in (9) is the log hazard ratio between never takers and compliers given no treatment. It can 
be interpreted as the magnitude of the unmeasured confounding because the differences 
between principal strata are attributable to the unmeasured confounding [5]. When Δ = 0 or 
, there is no unmeasured confounding.
We make the following observations about the bias of 2SPS method from (3.11): 1) When α 
= 1 and we treat α* as a known parameter and fix it at 1, that is the scenario when the 
survival outcomes of all principal strata follow exponential distributions and we also fit an 
exponential model in the second stage instead of estimating the shape parameter for a more 
general form of Weibull distribution; 2) When ρc = 1, every subject is a complier and (8) can 
be simplified as . Then we have . Setting ρc = 1, ρa = 0, 
and ρn = 0, (8) becomes 0 so that bias B2sps = 0 when a randomized controlled trial has 
perfect compliance; 3) When there is no causal effect ( ), all terms in (8) cancel out 
and we have B2sps = 0; 4) When ρa = 0 and , there is no confounding because there are 
no always takers and never takers can’t get treatment so that the confounding can only be 
attributable to the difference between never takers and compliers given no treatment[5]. 
However, (8) can not be reduced to 0 under this setting so that the bias of 2SPS method 
B2sps is generally not 0 even when there is no confounding. 5) λ, the scale parameter of the 
censoring distribution is involved in bias equation (9), which coincides with the results in 
Struthers and Kalbfleisch[17].
We can analyze how parameters influence the relationship between the magnitude of 
confounding and bias using derived closed form expression (9). For the purpose of 
demonstration only, here we create four scenarios in which there are no always takers. The 
results are revealed in Figure 1 (a)-(d).
In Figure 1, we can clearly see that the bias of the 2SPS method is not 0 when there is no 
confounding. The bias increases with the larger shape parameter α of the survival function 
(within each principal stratum). The bias is the smallest when we have an decreasing hazard 
rate (α < 1) and the highest when we have an increasing hazard rate (α > 1). By comparing 
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Figure 1 (a) and (b), we also observe that the bias decreases as the compliance rate increases 
from 0.5 to 0.8. When the scale parameter (θc) is smaller, the bias is also smaller (Figure 1 
(a) vs. (c)). Although the probability of being randomly assigned to the treatment group is 
involved in computing the shape parameter of the second stage Weibull regression model, 
its effects on the bias are very small (compare Figure 1 (b) to (d)).
4. Two Stage Residual Inclusion (2SRI) Method
Similar to the 2SPS method, the 2SRI method involves two stage modeling [4]. In the first 
stage, we regress the treatment received Z on the IV-treatment assignment R and calculate 
the residual term E = Z − E (Z∣R). In the second stage, we fit a log linear model on both 
treatment received variable Z and residual E as,
(10)
, to estimate the regression coefficient λ1. This is 2SRI estimaor of the log causal hazard 
ratio. We derive the probability limit of the M.L.E of λ1 first and then calculate the 
asymptotic bias by taking the difference between this probability limit of the estimator and 
true log causal hazard ratio among compliers.
4.1. Probability limit of M.L.E of causal parameter
As discussed in a previous study[5], (10) is not the true model for the hazard function h(Y∣Z, 
E). In fact the true model includes the interaction term between Z and E. However, deriving 
the closed-form expression for the probability limit of the estimator from (10) is very 
difficult when (10) is not the true model. With one additional assumption that there are no 
always takers, (10) becomes the true model. We derive a closed-form expression of the 
probability limit of the estimator of causal parameter λ1 assuming that there are no always 
takers and thus (10) is the true model. Let Ê denote the residuals from the estimated binary 
regression model in the first stage. i.e., Ê = Z − Ê(Z∣R). When Ê is substituted for E, (10) 
becomes:
Let  and λ̂1 be the estimators (M.L.E) of  and λ1. As sample size n → ∞, Ê → E, 
, and . Thus, . To derive a closed form expression for the 
asymptotic bias, we need to first re-express λ1 in terms of the parameters specified in section 
2.3 under the principal stratification framework.
As shown in a previous study[5], under the no always taker assumption, the first stage 
binary regression is E(Z∣R) = ρa + ρcR and residual term E = Z − E (Z∣R), thus the residual 
term can be re-expressed as E = Z − ρa − ρcR. Since {Z, E} has an one to one relationship 
with {Z, R}, we can establish the following equivalence between the model involving {Z, E} 
and the model involving {Z, R} for the second stage Weibull model:
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(11)
Under the no always taker assumption, the second stage Weibull regression model defined 
by (10) assumes the three underlying Weibull distributions with the same shape parameter 
but different scale parameters for subjects in the three different subgroups: 1) ~ Weibull(α*, 
K0) for those who are assigned to treatment and receive the treatment actually (Z = 1, R = 1). 
Only compliers are in this group; 2) ~ Weibull(α*, K1) for those who are assigned to 
treatment but do not receive the treatment actually (Z = 0, R = 1), This group has only never 
takers; 3) ~ Weibull(α*, K2) for those who are assigned to control and do not receive the 
treatment (Z = 0, R = 0), both never takers and compliers are in this group. There are no 
subjects that are assigned to control but still take the active treatment (Z = 1, R = 0) under 
the assumption of no always takers. Thus, the M.L.E of α*, K0, K1, K2 are derived by 
maximizing the likelihood function Ln(α*, K0, K1, K2) that consists of products of three 
Weibull densities: Weibull(α*, K0), Weibull(α*, K1), and Weibull(α*, K2).
Let α̂* denote the M.L.E of α* and set , 
the expectation of score equation derived from profile likelihood of α*, to 0 and let  be the 
solution. Under the assumptions stated in section 2 and consistency of the M.L.E, the 
probability limit of the estimator α̂* is . Details are given in Appendix D. With the 
parameters of principal strata defined,  can be solved numerically using a root-finding 
algorithm. Let K̂0, K̂1, K̂2 be the M.L.Es of two scale parameters K0, K1, K2. Once the value 
of  is determined, we compute the probability limits of the estimators K̂0, K̂1, K̂2 as 
follows:
(12)
and
(13)
and
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(14)
The derivation of (12),(13) and (14) is detailed in Appendix D. Based on (11), we can 
establish the following three equations with all possible combination of values of Z and R 
excluding the always takers scenario (Z=1, R=0).
1. When Z=1 and R=1, there are only compliers in this subgroup.
(15)
2. When Z=0 and R=1, there are only never takers in this subgroup.
(16)
3. When Z=0 and R=0, there are mixture of both never takers and compliers in this 
subgroup.
(17)
We then derive the closed form expression for the causal parameter λ1 by solving (15),(16), 
and (17) for λ1 as follows:
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4.2. Bias analysis
To compute asymptotic bias of the 2SRI method, we subtract the true log hazard ratio ϕ 
from the closed-form expression of λ1.
(18)
We can re-parameterize  in (18) in the way as in Section 3 and let . From the 
derived expression of asymptotic bias of 2SRI estimator, we can make the following 
observations: 1) When α = 1, the survival outcome within a principal stratum follows an 
exponential distribution. If we treat α* as known and set α* = 1, it means we fit an 
exponential regression model in the second stage; 2) When there is perfect compliance (ρc = 
1), we have B2SRI = 0. In this scenario, . By plugging ρc = 1 into (18), we can easily 
verify the results; 3) When there is no confounding ( ), B2SRI = 0; 4) When there is no 
causal effect ( ), B2 SRI is not 0; 5) λ, the scale parameter of the censoring distribution 
is involved in bias equation (18), similar to the findings for 2SPS method.
We can analyze how parameters influence the relationship between the magnitude of 
confounding and bias from the 2SRI method using (18). Similar to the previous section, four 
scenarios were created assuming there are no always takers. The results are shown in Figure 
2 (a)-(d). In Figure 2, it is apparent that the bias of the 2SRI method is 0 when there is no 
confounding. Intuitively, under the condition of no confounding, substituting the term of the 
estimated residuals in the second stage survival model has no effect on the estimate of the 
causal parameter. By comparing Figure 2 (a) and (b), we also observe that the bias decreases 
as the compliance rate increases from 0.5 to 0.8. When the scale parameter (θc) is smaller, 
the bias tends to be smaller (Figure 2 (a) vs. (c)). The probability of being randomly 
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assigned to the treatment group has very small impact on the bias (compare Figure 2 (b) to 
(d)).
5. Simulation
5.1. Simulation algorithm
We follow the five step algorithm used by Cai et al.[5] to generate data for a simulation 
study. In the first step, a data set of N subjects is generated. Always takers, compliers, and 
never takers among these subjects are generated from a multinomial distribution with 
probabilities {ρa, ρc, ρn}. At the second step, treatment assignment status R is generated for 
each subject with probability P(R = 1) = ρr. Because outcome in the present study is time to 
event, we modified step 3 to generate potential survival time {T0, T1} and censoring time 
{L0, L1} for each principal stratum based on the parameters , , , , , , λ. For 
instance, if a subject is a complier, the potential time to death under control  is generated 
from weibull (α, ) and the potential time to death under treatment  is generated from 
weibull (α, ). The potential censoring time { , } are generated from weibull(α, λ). At 
step 4, we use compliance status (always taker, complier, or never taker) and treatment 
assignment status R to determine the treatment received status Z. For instance, if a subject is 
a complier and assigned to treatment group (R = 1), then Z = 1. If a subject is an always 
taker but assigned to the control group, then Z = 0. At step 5, the observed survival time and 
censoring time are generated as follows:
and finally observed follow up time and censoring indicator are given as:
5.2. Simulation results
To demonstrate the consistency between the derived closed form expressions and the 
asymptotic biases from the 2SPS and 2SRI approaches under the assumption of no always 
takers (ρa = 0), we ran the simulation 2000 times, with the sample size n=10000, according 
to the same parameter settings presented in Figure 1 d) and Figure 2 d). Table 1 shows 
simulation results from 4 scenarios (α = 0.5, 1, 1.5, 2). As shown in this table, the biases 
from simulated results are consistent with the values computed with the derived analytic 
formula for both the 2SPS and 2SRI Weibull models. We also considered 2SPS and 2SRI 
Cox models (the second stage regression is a Cox model instead of a Weibull model). The 
pattern of the biases from 2SPS and 2SRI Cox models remains the same as for the 2SPS and 
2SRI Weibull models respectively. With decreasing hazard (α = 0.5), the bias from using the 
2SPS approach is smaller than the bias from the 2SRI approach. When the hazard is constant 
or increasing (α ≥ 1), the results are mixed. With stronger negative confounding, the 2SPS 
method produces smaller bias than the 2SRI method. However, with no confounding or 
stronger positive confounding, the 2SPS method produces larger bias than the 2SRI method.
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To evaluate the performance of both 2SPS and 2SRI methods in the setting where there are 
always takers, we simulated the data with various combination of parameters based on the 
following settings: i) Shape parameter α varies among {0.5, 1, 2}, which represent 
decreasing, constant, and increasing hazard scenarios; ii) Probabilities of being always 
takers ρa and compliers ρc were set to 3 combinations: {0.2, 0.7}, {0.7, 0.2}, and {0, 0.5}. In 
this way, low, medium, and high levels of compliance were represented; iii) probability of 
being assigned to treatment ρr were set to {0.1, 0.5} to reflect both new and relatively 
established treatments; iv) Scale parameter of censoring distribution were set to {0.5, 1, 2}; 
v) Each of the parameters , ,  was set to {0.5, 1, 3} separately. Thus, 1458 possible 
combinations were created. For each setting, we generated 10,000 observations and fit the 
2SPS and 2SRI models to the data. This process was repeated 2000 times.
The results are presented in Figure 3. The magnitude of bias increases with increasing 
magnitudes of unmeasured confounding. As the value of shape parameter α increases, the 
magnitude of bias increases. In the scenarios with decreasing hazard, the 2SPS method 
outperforms the 2SRI method. The 2SRI method tends to have larger asymptotic bias when 
the magnitude of unmeasured confounding is large. In the scenarios with constant hazard, 
the 2SPS method slightly outperforms the 2SRI method when the magnitude of unmeasured 
confounding is large. In the scenarios with increasing hazard, both approaches produce 
larger biases. The 2SRI method performs better when the magnitude of unmeasured 
confounding is small. When there are always takers, the 2SRI method could be biased even 
when there is no measured confounding. We also compared the two methods using mean 
square error and the conclusions remain the same (4).
6. Seer-Medicare Prostate Cancer Study
Prostate cancer is the highest prevalence non-skin malignancy among American men (In 
2011, there were an estimated 2,707,821 men living with prostate cancer in the United 
States. The number of deaths was 23.0 per 100,000 men per year). Unlike prostate cancers 
that are diagnosed at an early stage, locally advanced prostate cancer is associated with 
substantial morbidity and mortality. Radiation therapy is a common treatment for locally 
advanced prostate cancer. Two randomized trials recently demonstrated that radiation 
therapy reduces mortality for men with locally advanced tumors who also receive systemic 
androgen deprivation[9, 10]. However, both trials excluded elderly patients and those with 
early stage, PSA-screen detected cancer and therefore had less generalizability, a common 
criticism of randomized evidence. Therefore, we applied two-stage IV methods to evaluate 
survival outcomes in locally advanced prostate cancer, assessing survival outcomes of 
androgen deprivation therapy with or without radiation therapy in comparison to the 
randomized trials.
We analyzed data from the Surveillance, Epidemiology and End Results (SEER)-Medicare 
database. The SEER-Medicare database links patient demographic and tumor-specific data 
collected by SEER cancer registries to Medicare claims for inpatient and outpatient care. We 
considered patients with prostate cancer diagnosed between January 1, 1995 and December 
31, 2007 in SEER with follow up through December 31, 2010 in Medicare. The following 
patients were excluded: 1) older than age 85; 2) with unknown urban category; 3) in hospital 
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referral regions (HRR) with less than 50 patients; 4) with unknown distance to the closest 
radiation facility; 5) patients who died within the first 9 months of the study. A total of 
31,541 patients were selected and categorized as receiving androgen deprivation with or 
without radiation therapy.
The cohort was divided into the following three groups: 1) patients with American Joint 
Commission on Cancer (AJCC) Tumor stage (T-stage) of T2 or T3 and aged 65-75 (called 
the RCT Cohort). The patients in the “RCT Cohort” are most comparable to the patients 
from the two randomized studies of androgen deprivation with or without radiation 
therapy[9, 10]; 2) elderly patients under-represented or excluded from the published 
randomized trials with T-stage T2 or T3, aged 76-85 (called the “Elderly Cohort”); and 3) 
patients with early stage, PSA-screen detected cancer with T-stage T1 disease who were 
excluded from the published randomized trials (called the “Screen-Detected Cohort”).
The study by Widmark et al.[9] included men from 47 centers in Europe diagnosed between 
February, 1996 and December, 2002. 875 patients with locally advanced prostate cancer 
(T3; 78%; prostate-specific antigen (PSA) ≤ 70 ng/mL; N0; M0) were enrolled. 439 patients 
were randomly assigned to androgen deprivation alone and the other 436 patients received 
androgen deprivation with radiation therapy. The study by Warde et. al. enrolled 1,205 
patients with locally advanced (T3 or T4) prostate cancer, organ-confined disease (T2) with 
either PSA >40 ng/mL or PSA >20 ng/mL and a Gleason score of 8 or higher between 1995 
and 2005. 1205 patients were randomly assigned to receive the androgen deprivation alone 
(n=602) or androgen deprivation with radiation therapy (n=603). The hazard ratios for 
overall mortality reported previously [9] and [10] were 0.68 (95% CI 0.52–0.89) and 0.77 
(95% CI 0.61–0.98). For ease of comparison, we combined the results of the randomized 
trials using weighted-average meta-analysis. The meta-analytic HR was 0.73 (0.61–0.87).
To assess the effectiveness of androgen deprivation with or without radiation therapy in 
reducing overall mortality (death from any cause), we performed two-stage IV Weibull 
regression analysis (2SPS and 2SRI) using a local area treatment rate instrument and 
controlling for the propensity score. The local area treatment rate instrument was defined as 
the proportion of patients who received definitive treatment (surgery or radiation therapy) 
among all patients with prostate cancer in the hospital referral region (HRR) and we 
categorized this instrument into a binary variable according to its median. This IV measures 
the aggressiveness of local area treatment and captures regionally distinct structural care 
variation not fully explained by patient characteristics. The IV was strongly associated with 
treatment assignment and balanced important prognostic factors [3]. The propensity score 
model included potential confounding variables including age, race, ethnicity, clinical T 
stage, N stage, and World Health Organization tumor grade, 17 categories of co-morbid 
disease, urban residence, and census track median income.
As shown in Table 2, there is variability in the estimated HRs obtained from the 2SPS and 
2SRI methods. We estimated the shape parameter α ≈ 1.6 from the data. Using Figure 3, we 
can see that the bias for both the 2SPS and 2SRI methods is the largest when we have an 
increasing hazard (α > 1), even when the magnitude of unmeasured confounding is 
relatively small. When the hazard function is a decreasing one (α < 1), the 2SPS method 
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produces more stable and less biased estimates than the 2SRI method. In this case, 2SPS 
may be a more appropriate approach to use. In the RCT Cohort, the estimated HRs 
(HR=0.96) from both IV methods are much larger than the meta-analytic HR from the two 
randomized studies. Note that the confidence intervals are also much larger in both IV 
analyses than in the original RCTs. In the published RCTs, the authors concluded that there 
was a statistically significant treatment effect (combined therapy is better) whereas from our 
IV analysis, we can’t draw this conclusion. In the total study sample and separately in the 
RCT Cohort and the Screen-Detected Cohort, the two IV estimates are quite similar. 
However, for the Elderly Cohort, the estimate from the 2SPS method is different from the 
estimate from the 2SRI method.
7. Discussion
Many clinical and health services studies are using health care databases to compare the 
treatment effectiveness for drug and surgical therapies, but are prone to unmeasured 
confounding. Two stage IV methods have been gaining popularity among clinical 
researchers because these methods provide a relatively simple approach to analyzing 
survival outcome studies in the presence of unmeasured confounding. However, current 
knowledge about potential bias in estimating the log causal hazard ratio is limited. As 
demonstrated in our prostate cancer study, the large treatment effects estimated from two 
stage IV methods could be attributable to potential bias. We have derived closed-form 
expressions for the asymptotic bias of the 2SRI and 2SPS approaches assuming the survival 
times follow a Weibull distribution with shape parameter α and scale parameter K. We have 
demonstrated that these analytic results are consistent with our simulation results.
For binary outcomes, two previous studies[5, 18] demonstrated that the bias in the treatment 
effect estimated using the 2SRI approach increases as the magnitude of confounding 
increases. In this current work, we have shown analytically and by simulation that the 2SRI 
and 2SPS approaches are both biased in estimating the causal hazard ratio among compliers. 
In some situations when the hazard is decreasing (e.g among patients who have recently 
received a kidney transplantation), the 2SPS method is less biased than the 2SRI method and 
could be a more appropriate method to use. When the hazard is an increasing function, both 
IV methods may produce very large bias even under a moderate amount of unmeasured 
confounding. In this case, we recommend exercising caution when interpreting results from 
two-stage IV survival models.
We have shown that even when all IV assumptions are met, both the 2SRI and the 2SPS 
methods could fail to consistently estimate the causal hazard ratio among compliers. Our 
analytic results for bias may help to guide researchers in deciding when the bias is likely to 
be reasonably small so that two stage IV methods may be reasonably applied. Furthermore, 
in a sensitivity analysis approach, one may estimate the shape parameter and the censoring 
proportion among patients assigned to treatment or control from the data. With the shape 
parameter and censoring proportions fixed based on our known data the level of the 
unmeasured confounding could be varied to examine how the estimates would change, as 
shown in Figures 1 and 2. Alternative methods include partial likelihood estimation [19].
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Appendix
Appendix A: Mixture of Weibull Distributions
Prove the distribution function of observed survival time T conditional on random 
assignment R can be expressed as the following equations:
(A.1)
and,
(A.2)
In the above equations, AT represents always takers, C represents compliers, and NT 
represents never takers. Other definitions of parameters and distributions that are used in the 
proof are given below:
no defiers under monotonicity assumption
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Proof
F(T∣R = 1) can be expressed as:
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F(T∣R = 0) can be expressed as:
Appendix B: Proofs related with Derivation of Closed Form Solution
1. Assume survival time T ~ Weibull(α, K) and censoring time L ~ Weibull(α, λ). Let 
Y = min(T, L) and δ = I(T ≤ L). Show that
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and,
(B.1)
Proof:
Thus, 
2. Assume survival time T is a mixture of three Weibull distributions with Density 
. T1 ~ Weibull(α, K1), T2 ~ Weibull(α, K2), and T3 ~ 
Weibull(α, K3). The weights are p1, p2, p3 and . The censoring time L ~ 
Weibull(α, λ). Let Y = min(T, L) and δ = I(T ≤ L). Show that
(B.2)
Proof:
Wan et al. Page 20
Stat Med. Author manuscript; available in PMC 2016 June 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
3. Given X follows a Weibull distribution (α*, K). Show that
(B.3)
Proof:
4. Given X follows a Weibull distribution (α*, K). Show that
(B.4)
Proof:
5. Given X follows a Weibull distribution (α*, K). Show that
(B.5)
Proof:
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6. Let Ti denote the survival time and Ci denote the censoring time for subject i. Ti 
and Ci are independent. Ti ~ weibull(α, K), and Ci ~ weibull(α, λ). Let Yi = min(Ti, 
Ci) denote observed follow-up time and δi be the indicator variable δi = (Ti ≤ Ci). 
Show that:
(B.6)
Proof:
Let  and use (B.1)
Both E(Yi δi) and E(Yi) E (δi) have the same integral functions. Thus,
Similarly, we can establish the following:
Appendix C: Derivation of probability limits of M.L.E of α, K0, K1 for 2SPS
Let Y = min(T, C) be observed follow-up time and δ = I(T ≤ C) be the censoring time. The 
subjects are assigned to either treatment group (R = 1) or control group (R = 0). The 
distribution of each subgroup has different scale parameter K but the same shape parameter 
α*. Thus, likelihood function of observed follow up time Y can be written as:
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For treatment assignment group and control assignment group, subjects are from compliers 
(c), never takers (nt), and always takers (at). Let nR1, nR0 denote number of subjects 
assigned to treatment (R = 1) and control (R = 0). Let nR1, at, nR1, nt, nR1, c denote number of 
always takers, never takers, and compliers that are assigned to treatment group. nR1, at + 
nR1, nt + nR1, c = nR1. Let nR0, at, nR0, nt, nR0, c denote number of always takers, never takers, 
and compliers, who are assigned to control group.nR0,at + nR0, nt + nR0, c = nR0. Therefore, 
the likelihood can be rewritten as:
Next, the log likelihood function is:
To derive the M.L.E of K0, K1, take the first derivative of l(y) with respect to K0, K1 and set 
score equation to 0, we have
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(C.1)
and,
(C.2)
To derive the M.L.E of α*, take the first derivative of l(y) with respect to α* and set score 
equation to 0 and replace K1, K0 with the expressions (C.1) and (C.2), we have
M.L.E α̂* is the solution to the above equation. Next, divide both sides by total number of 
subject n, we have
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As nR1, nR0, nR1, at, nR1, nt, nR1, c, nR0, at, nR0, nt, nR0, c → ∞, the score equation converges to 
the following:
(C.
3)
Use the results from Appendix B, we can derive the following:
and,
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Let  be the solution to the equation (C.3). By the consistency of M.L.E, Thus, we have 
 Next, substitute α̂* into equation (C.1)
Asymptotically, it converges to
Similarly, K̂1 converges to
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Appendix D: Derivation of probability limits of M.L.E of α, K0, K1, K2 for 
2SRI
Under the no AT assumption, we can find an expression for λ1 as follows. The first stage 
regression can be re-expressed as following:
Note that Z, E and Z, R are one-to-one correspondence. Knowing Z, E will let us know Z, R 
and vice versa. Under no always taker assumption, we observe three subgroups 1) Z = 1, R = 
1. Only compliers in this group; 2) Z = 0, R = 1, Only never takers in this group; 3) Z = 0, R 
= 0, both never takers and compliers in this group. There are no patients that are assigned to 
control but still takes on active treatment (Z = 1, R = 0). For the 3 subgroups, essentially we 
are fitting 3 Weibull distributions with the same shape parameter α* and 3 different shape 
parameter K0, K1, K2 with Weibull regression model: logh(t) = λ0 + λ1 Z + λ2 E
The likelihood function is:
The log likelihood is:
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Take the first derivative of l(y) with respective to K0, K1, K2 respectively and set score 
equation to 0, then we have
(D.1)
(D.2)
(D.3)
Take the first derivative of l(y) with respective to α* and replace K0, K1, K2 with expression 
(D.1),(D.2),(D.3), then we have:
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M.L.E α̂* is the solution to the above score equation. Next, divide the equation by total 
sample size n,
As sample sizes in each principal strata → ∞, the score equation will converge to:
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(D.
4)
where,
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 is the solution to the equation (D.4). Thus, . Probability limits of M.L.E of K0 
can be derived as following:
Similarly, for K1, K2,
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Appendix E: Assumption of the same shape parameter for survival and 
censoring distributions
In section 2 of the manuscript, we made the assumption that both time to event and 
censoring time have the same shape parameter so that close form solution could be derived. 
To evaluate the potential impact on the bias when the time to event and censoring time have 
two different shape parameters and the assumption is violated, we re-evaluated the scenario 
in the table 1 with the shape parameter α = 0.5. We set the shape parameter of censoring 
distribution to be 1.2 and compared the differences. We found that the differences in bias of 
2SPS between two scenarios ranges from 0.01 to 0.018 (δ varies from -2 to 2). For 2SRI 
approach, the differences ranges from 0.001 to 0.13. These differences are attributable to the 
different censoring proportions between two scenarios. The shape of relationship between 
bias and δ remains approximately unchanged (data not shown). It should be noted that under 
the assumption of having the same shape parameters for both survival time and censoring 
time, the maximum likelihood estimator based on the survival likelihood that does not 
incorporate the assumption of the shape parameters being the same is not fully efficient.
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Figure 1. 
Plot of bias against magnitude of unmeasured confounding Δ using 2SPS method:(a) P (R = 
1) = 0.8, ρa = 0, ρc = 0.5, , . (b) P (R = 1) = 0.8, ρa = 0, ρc = 0.8, , 
. (c) P (R = 1) = 0.8, ρa = 0, ρc = 0.5, , . (d) P (R = 1) = 0.5, ρa = 0, 
ρc = 0.8, , . The different colour of solid line corresponds to different shape 
parameter: black (α = 0.5), red (α = 1), and green (α = 2).
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Figure 2. 
Plot of bias against magnitude of unmeasured confounding Δ using 2SRI method: (a) P (R = 
1) = 0.8, ρa = 0, ρc = 0.5, , . (b) P (R = 1) = 0.8, ρa = 0, ρc = 0.8, , 
.(c) P (R = 1) = 0.8, ρa = 0, ρc = 0.5, , . (d) P (R = 1) = 0.5, ρa = 0, 
ρc = 0.8, , . The different colour of solid line corresponds to different shape 
parameter: black (α = 0.5), red (α = 1), and green (α = 2).
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Figure 3. 
Absolute bias in estimating log causal hazard ratio using two stage IV methods (X-axis is 
the magnitude of confounding Δ, Y-axis is the absolute bias). For 2SRI method or 2SPS 
method, the biases computed for each of 1458 possible scenarios were grouped by the 
magnitude of shape parameter α (decreasing hazard for α = 0.5, constant hazard for α = 1, 
and increasing hazard for α = 2) and the magnitude of confounding Δ (larger values 
represent lager confounding effects and 0 represents no confounding).
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Figure 4. 
Mean square error in estimating log causal hazard ratio using two stage IV methods (X-axis 
is the magnitude of confounding Δ, Y-axis is the Mean Square Error). For 2SRI method or 
2SPS method, the mean square error computed for each of 1458 possible scenarios were 
grouped by the magnitude of shape parameter α (decreasing hazard for α = 0.5, constant 
hazard for α = 1, and increasing hazard for α = 2) and the magnitude of confounding Δ 
(larger values represent lager confounding effects and 0 represents no confounding).
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Table 2
Bias in estimating causal hazard ratio parameter for prostate cancer study
Outcome Group IV2sri IV2sps
All cause mortality Total (n=31541) 0.57(0.17-1.06) 0.59(0.19-1.09)
RCT Cohort (n=12924) 0.96(0.18-5.81) 0.97(0.18-5.94)
Elderly Cohort (n=14340) 0.74(0.20-1.83) 0.96(0.26-2.35)
Screen-Detected Cohort (n=4277) 0.34(0.02-2.99) 0.35(0.03-3.22)
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